drugset / Trial / NCT03664882

Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants

NCT03664882

Phase 3 Completed 240 enrolled Sanofi
RandomizedParallel-groupDouble-blindTreatment

Summary

Primary Objectives: * To demonstrate that the aggravation of seasonal allergic rhinitis symptoms in the presence of pollutants is observed using an Environmental Exposure Unit. * To evaluate the efficacy of fexofenadine hydrochloride in subjects suffering from seasonal allergic rhinitis symptoms aggravated in the presence of diesel exhaust particulates. Secondary Objective: To evaluate the safety of a single dose of fexofenadine hydrochloride 180 mg.

Timeline

Start
2018-09-17
Primary completion
2019-01-03
Completion
2019-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fexofenadine Unknown 180 mg Oral